MedTrace Logo

An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes

NCT05107063 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2972

Last updated 2021-11-04

No results posted yet for this study

Summary

This study investigated the effectiveness of pravastatin on renal function in Korean dyslipidemic patients with Type 2 diabetes.

Conditions

  • Dyslipidemia Associated With Type II Diabetes Mellitus

Interventions

DRUG

Pravastatin

Routine initiation dose was 10 mg, 20 mg or 40 mg single dose once daily. Depending on patient response, dose could have been increased up to 40 mg. Maintenance dose was 10-40 mg once daily.

Sponsors & Collaborators

  • Daiichi Sankyo Korea Co., Ltd.

    collaborator INDUSTRY

  • Daiichi Sankyo

    lead INDUSTRY

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-20
Primary Completion
2018-04-19
Completion
2018-04-19
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05107063 on ClinicalTrials.gov